Clinical and cytogenetic characteristics of 21 patients achieving complete remission in response to T + E
| Age, y/sex . | Prior sAML/treatment . | PS . | Comorbidities . | Cytogenetics . | Arm . | DFS/OS arm . |
|---|---|---|---|---|---|---|
| 85/male | No/no | 1 | Aortic aneurysm, HBP nephrolithiasis | 47 XY, +8 | A | 10.9/13 |
| 77/male | No/no | 2 | Abdominal aneurysm, HBP nephrolithiasis, gastrointestinal bleed | 47 XY, +11 | A | 6.6*/37.4+ |
| 76/male | No/no | 2 | CAD, diabetes, sleep apnea | NG | B | 2.8/3.7 |
| 80/male | No/no | 2 | COPD, lower gastrointestinal bleed, HBP | 46 XY | A | 14.1/26.1 |
| 82/male | Yes/yes | 2 | CAD/stents | 46 XY | B | 10.7/14 |
| 75/female | Yes/no | 2 | CAD/stents, atrial fibrillation peripheral vascular disease | 46 XX, −20q | B | 21/22.8 |
| 79/male | Yes/yes | 1 | Prostate cancer/XRT, HBP, GERD | 45XY,-7,t(3;3) | B | 5.9/16.3 |
| 81/female | No/no | 1 | HBP, ↑ lipids, gout | 46XY | A | 21.3*/33.8+ |
| 81/male | No/no | 2 | Prostate cancer/XRT esophageal stricture | 47 XY,+13 + 9q34 | B | 21.1/22.6 |
| 88/male | Yes/yes | 1 | HBP, pneumonia | 46XY | B | 2.2/14.3 |
| 74/male | No/no | 2 | CAD, DOE, ”B”symptoms | ND | A | 7.0/23.6 |
| 74/male | Yes/yes | 2 | Prostate cancer/XRT, DOE, CAD carotid endarterectomy | 46XY | A | 6.9/12 |
| 76/male | Yes/yes | 1 | CAD/post-CABG, BPH | 45XY,dic(1;11) der 2, t(1;2) | A | 18.8*/27.5+ |
| 77/male | No/no | 2 | CAD, DOE, stomatitis | 46XY | A | 4.7/6.2 |
| 76/male | No/no | 1 | Osteoarthritis | 46XY,t(2;11) | A | 5.3/19.3 |
| 71/male | Yes/yes | 1 | HBP, prostate cancer, Grover disease | 46XY | A | 13.7/23.2+ |
| 79/female | No/no | 2 | None | ND | A | 6.6/13 |
| 72/male | Yes/yes | 2 | Myeloma, pneumonia, HBP GERD, hypothyroidism, leukemia cutis | 46XY | A | 4.6/6.1 |
| 75/male | No/no | 2 | HBP, pharyngeal obstruction | 47XY,+8 | A | 7.8/10.8 |
| 71/female | Yes/no | 1 | Arthralgias, fatigue | 46XX | A | 16+/17.5+ |
| 76/male | Yes/no | 1 | HBP, BPH | 46XX | A | 16+/17+ |
| Age, y/sex . | Prior sAML/treatment . | PS . | Comorbidities . | Cytogenetics . | Arm . | DFS/OS arm . |
|---|---|---|---|---|---|---|
| 85/male | No/no | 1 | Aortic aneurysm, HBP nephrolithiasis | 47 XY, +8 | A | 10.9/13 |
| 77/male | No/no | 2 | Abdominal aneurysm, HBP nephrolithiasis, gastrointestinal bleed | 47 XY, +11 | A | 6.6*/37.4+ |
| 76/male | No/no | 2 | CAD, diabetes, sleep apnea | NG | B | 2.8/3.7 |
| 80/male | No/no | 2 | COPD, lower gastrointestinal bleed, HBP | 46 XY | A | 14.1/26.1 |
| 82/male | Yes/yes | 2 | CAD/stents | 46 XY | B | 10.7/14 |
| 75/female | Yes/no | 2 | CAD/stents, atrial fibrillation peripheral vascular disease | 46 XX, −20q | B | 21/22.8 |
| 79/male | Yes/yes | 1 | Prostate cancer/XRT, HBP, GERD | 45XY,-7,t(3;3) | B | 5.9/16.3 |
| 81/female | No/no | 1 | HBP, ↑ lipids, gout | 46XY | A | 21.3*/33.8+ |
| 81/male | No/no | 2 | Prostate cancer/XRT esophageal stricture | 47 XY,+13 + 9q34 | B | 21.1/22.6 |
| 88/male | Yes/yes | 1 | HBP, pneumonia | 46XY | B | 2.2/14.3 |
| 74/male | No/no | 2 | CAD, DOE, ”B”symptoms | ND | A | 7.0/23.6 |
| 74/male | Yes/yes | 2 | Prostate cancer/XRT, DOE, CAD carotid endarterectomy | 46XY | A | 6.9/12 |
| 76/male | Yes/yes | 1 | CAD/post-CABG, BPH | 45XY,dic(1;11) der 2, t(1;2) | A | 18.8*/27.5+ |
| 77/male | No/no | 2 | CAD, DOE, stomatitis | 46XY | A | 4.7/6.2 |
| 76/male | No/no | 1 | Osteoarthritis | 46XY,t(2;11) | A | 5.3/19.3 |
| 71/male | Yes/yes | 1 | HBP, prostate cancer, Grover disease | 46XY | A | 13.7/23.2+ |
| 79/female | No/no | 2 | None | ND | A | 6.6/13 |
| 72/male | Yes/yes | 2 | Myeloma, pneumonia, HBP GERD, hypothyroidism, leukemia cutis | 46XY | A | 4.6/6.1 |
| 75/male | No/no | 2 | HBP, pharyngeal obstruction | 47XY,+8 | A | 7.8/10.8 |
| 71/female | Yes/no | 1 | Arthralgias, fatigue | 46XX | A | 16+/17.5+ |
| 76/male | Yes/no | 1 | HBP, BPH | 46XX | A | 16+/17+ |
sAML indicates secondary AML (MDS, treatment-related)/treatment for MDS; PS, performance status; HBP, high blood pressure; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; XRT, irradiation; GERD, gastroesophageal reflux disease; DOE, dyspnea on exertion; CABG, coronary artery bypass graft; and BPH, benign prostatic hyperplasia.
Reversion to MDS.